Smart sensors could revolutionize MG monitoring

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of autoimmune MG with or without history of thymoma * MGFA severity class IIa/b, IIIa/b or IVa/b at the screening visit * Diagnosed gMG through one or more of the following: * Positive acetylcholine receptor antibody (AChR Ab) test, or * Abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS), or * Documented positive response to standard MG therapies (e.g., AChE inhibitors, IVIG/PLEX, FcRn antagonists or C5 inhibitors) * Currently initiating treatment with VYVGART® or VYVGART Hytrulo® * Physically and cognitively able to provide informed consent and adhere to the study procedures, as determined by the investigator. * Ambulatory, defined as the ability to walk at least 10 meters independently, with or without the use of an assistive device. * Speaks and reads English fluently Exclusion Criteria: * Inability to perform essential activities of daily living required for independent living, such as dressing, bathing, toileting, or eating without assistance. * Presence of neurological or orthopedic conditions unrelated to MG that, in the investigator's judgment, significantly impair gait or daily functioning. * Any clinically significant medical, laboratory, or psychiatric condition that, in the opinion of the investigator, could interfere with study participation or data integrity. * Current residence in a long-term care or institutional facility (e.g., nursing home, skilled nursing facility), receipt of hospice care, or incarceration. * MGFA severity classification of Class I or Class V (myasthenic crisis). Pregnant or breastfeeding women. * Concurrent participation in another interventional clinical trial (participation in observational studies, biomarker studies, or registries is permitted).